ABCAM PLC Appointment of Non-Executive Director (9945Y)

TIDMABC

RNS Number : 9945Y

ABCAM PLC

12 September 2022

ABCAM PLC

Appointment of Non-Executive Director

12 September 2022, Cambridge, UK - Abcam plc (AIM: ABC; Nasdaq: ABCM) ("Abcam", "Company"), a global leader in the supply of life science research tools, is pleased to announce the appointment of Luba Greenwood as a non-executive Director with immediate effect.

Luba's experiences focus on business development and strategy. She is a veteran biotech, pharmaceutical, tech, and life sciences investor and company builder. Luba has held a number of senior leadership and board positions in the healthcare industry. Currently, she serves as the managing partner of the Dana Farber Cancer Institute Venture Fund, Binney Street Capital (BSC), which she has built and launched. Luba is also the CEO of Kojin Therapeutics, a BSC portfolio company. Her previous experience includes increasing levels of responsibility at Google Life Sciences, Verily and F. Hoffman-La Roche.

Luba has extensive board experience, and currently serves on the board of directors of the following private institutions: MassBio, BenchSci, and In8Bio, Inc.

Peter Allen, Chairman of Abcam said: "I am delighted to welcome Luba to the Board of Abcam. Luba has had a distinguished career and her experience and expertise, particularly her understanding of Life Sciences, Technology and Healthcare will be a valuable asset to the Company as we continue to partner in this area and work towards our long-term growth plans."

Following Luba's appointment, the composition of each of the Board Committees is confirmed as follows:

 
 Board Committee            Membership 
 Nomination Committee       Peter Allen (Chair) 
                             Mara Aspinall 
                             Giles Kerr 
                           ========================== 
 Remuneration Committee     Sally W. Crawford (Chair) 
                             Mara Aspinall 
                             Peter Allen 
                             Giles Kerr 
                             Mark Capone 
                           ========================== 
 Audit and Risk Committee   Giles Kerr (Chair) 
                             Mara Aspinall 
                             Sally W. Crawford 
                           ========================== 
 

AIM Rules disclosures

Luba Greenwood (age 43) holds or has held directorships in the five years preceding her appointment at Abcam as follows:

 
 Current Directorships                  Previous Directorships 
                                         (last five years) 
 Kojin Therapeutics, Inc.               Entrinsic Bioscience, LLC 
                                       ============================= 
 Massachusetts Biotechnology Council,   Luca Biologics Inc. 
  Inc.(MassBio) 
                                       ============================= 
 Scinapsis Analytics, Inc. (BenchSci)   Brooklyn Immunotherapeutics, 
                                         Inc 
                                       ============================= 
 OS Acquisition Corp. (OS Fund)         Falcon Ridge Partners, LLC 
                                       ============================= 
 In8Bio, Inc.                           Dana Point Advisors, LLC 
                                       ============================= 
 

Save as disclosed above there are no additional disclosures to be made in accordance with Schedule Two paragraph (g) of the AIM Rules.

For further information, please contact:

 
Abcam                                                       + 44 (0) 1223 696 000 
Marc Perkins, Company Secretary 
 Tommy J. Thomas, CPA, Vice President, Investor Relations 
Numis - Nominated Advisor & Joint Corporate Broker          + 44 (0) 20 7260 1000 
Freddie Barnfield / Duncan Monteith 
Morgan Stanley - Joint Corporate Broker                     + 44 (0) 207 425 8000 
Tom Perry / Luka Kezic 
FTI Consulting                                              + 44 (0) 20 3727 1000 
Ben Atwell / Lydia Jenkins 
 

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated antibodies, assays and other research tools to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.

Abcam's worldwide customer base of approximately 750,000 life science researchers uses Abcam's antibodies, reagents, biomarkers and assays. By actively listening to and collaborating with these researchers, the Company continuously advances its portfolio to address their needs. A transparent program of customer reviews and datasheets, combined with industry-leading validation initiatives, gives researchers increased confidence in their results.

Founded in 1998 and headquartered in Cambridge, UK, the Company has served customers in more than 130 countries. Abcam's ordinary shares are listed on the London Stock Exchange (AIM: ABC) and its American Depositary Shares (ADSs) trade on the Nasdaq Global Market (Nasdaq: ABCM).

For more information, please visit www.abcam.com or www.abcamplc.com

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this announcement that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements regarding Abcam's portfolio and ambitions, expected performance for second half 2021, as well as statements that include the words "expect," "intend," "plan," "believe," "project," "forecast," "estimate," "may," "should," "anticipate" and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: a regional or global health pandemic, including the novel coronavirus ("COVID-19"), which has adversely affected elements of our business, could severely affect our business, including due to impacts on our operations and supply chains; challenges in implementing our strategies for revenue growth in light of competitive challenges; developing new products and enhancing existing products, adapting to significant technological change and responding to the introduction of new products by competitors to remain competitive; failing to successfully identify or integrate acquired businesses or assets into our operations or fully recognize the anticipated benefits of businesses or assets that we acquire; if our customers discontinue or spend less on research, development, production or other scientific endeavours; failing to successfully use, access and maintain information systems and implement new systems to handle our changing needs; cyber security risks and any failure to maintain the confidentiality, integrity and availability of our computer hardware, software and internet applications and related tools and functions; failing to successfully manage our current and potential future growth; any significant interruptions in our operations; if our products fail to satisfy applicable quality criteria, specifications and performance standards; failing to maintain our brand and reputation; our dependence upon management and highly skilled employees and our ability to attract and retain these highly skilled employees; and the important factors discussed under the caption "Risk Factors" in Abcam's prospectus pursuant to Rule 424(b) filed with the U.S. Securities and Exchange Commission ("SEC") on 22 October 2020, which is on file with the SEC and is available on the SEC website at www.sec.gov, as such factors may be updated from time to time in Abcam's other filings with the SEC. Any forward-looking statements contained in this announcement speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. Abcam disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAFZGGLKLMGZZM

(END) Dow Jones Newswires

September 12, 2022 02:01 ET (06:01 GMT)